Welcome to MOAlifeplus

Key Moments.

2024.

History 2024

May. BLS-M22/M32 US Elevai Labs. Technology transfer

April. CI changed to “MOA Life Plus.Co.Ltd.

Key Moments.

2022.

History 2022

Aug. IND approval for phase 2/3 clinical trial of cervical precancer treatment (BLS-M07)

Mar. IND, applied for approval of clinical trial phase 2/3 IND (BLS-M07)

Mar. IND approval for phase 2 clinical trial of COVID-19 treatment (BLS-H01)

Key Moments.

2020.

History 2020

Oct. Phase 1 clinical trial of Duchenne muscular dystrophy treatment (BLS-M22) completed

Key Moments.

2019.

History 2019

Sep. Founded joint venture of Quintrigen with Weizmann Institute of Science (Israel) for p53 new-drug development.

Jun. Approval on clinical trial phase 3 IND of CIN drug (BLS-H01)

Jan. Designated DMD drug (BLS-M22) as development-stage orphan drug

Key Moments.

2017.

History 2017

Dec. Orphan drug designation of Duchenne muscular dystrophy drug (BLS-M22)

Key Moments.

2016.

History 2016

Jul. listed in Korea Exchange (KOSDAQ, technology special listing)

Key Moments.

2012.

History 2012

Sep.Certified PGA for immune-promotion functional food material

Key Moments.

2000.

History 2000

Jul. Certified company research center (KOITA)

Key Moments.

1999.

History 1999

Dec. Established Bioleaders .